Publications and Innovation
June 2017 – Sera's recent analytical study, “Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth” has been published in the June issue of Clinical Mass Spectrometry. The study details a rigorous analytical validation of Sera’s liquid chromatography/mass spectrometry (LC/MS) platform for sensitive later-generation Agilent mass spectrometers.
December 2016 – Published in the American Journal of Perinatology Reports, the authors of this article concluded that “the use of a prognostic test for reducing spontaneous preterm birth is a dominant strategy that could reduce costs and improve outcomes.” Other findings from the report state that preterm birth risk testing and intervention could result in:
October 2016 – Published in the peer-reviewed journal, Proceedings in Obstetrics and Gynecology, the authors present a clinical treatment protocol for testing women early in pregnancy with a validated biomarker test for preterm birth risk, and administering recommended interventions based on a woman’s individual risk. The paper, Preterm Birth: can we do better? discusses:
May 2016 – This study, published as an Editor’s Choice article in the May issue of American Journal of Obstetrics & Gynecology, concluded that a serum-based molecular predictor (the PreTRM test) predicts an asymptomatic pregnant woman’s individual risk of spontaneous preterm delivery. This information, early in her pregnancy, may provide clinical utility in identifying women at increased risk at an early stage of pregnancy and allowing for clinical intervention that may help prolong gestational age and improve neonatal outcome.
May 2016 – Published in Contemporary OB/GYN, this supplement captured proceedings of a panel discussion hosted by Sera Prognostics at the 2016 Society of Maternal-Fetal Medicine Annual meeting.
March 2016 - Sera Prognostics, Inc. presented data demonstrating correlation between ELISA and MRM-MS at the Society of Reproductive Investigation 2016 Annual Meeting. The results of the data demonstrated a two protein ELISA platform that is highly correlative with LC-MRM-MS results and generates sPTB risk scores with excellent classification performance.
Jay Boniface, PhD
Chief Scientific Officer